8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Is compounding Farxiga (dapagliflozin) legal? Review FDA approval history, current label indications, patent status, compounding pharmacy regulations, and safety data for this SGLT2 inhibitor.
A clinical review of dapagliflozin (Farxiga) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including DKA, Fournier gangrene, UTI, and volume depletion findings from post-market surveillance.
Complete timeline of Farxiga (dapagliflozin) FDA approvals, label expansions, boxed warning removals, and post-market safety communications from 2014 through 2025.
A detailed comparison of how the FDA and EMA reviewed, labeled, and post-market surveilled dapagliflozin (Farxiga/Forxiga), including approved indications, safety requirements, and post-approval commitments.
A complete guide to Farxiga (dapagliflozin) global regulatory history, FDA-approved indications, current prescribing label, and post-market safety data. Reviewed by the HealthRX medical team.
Every FDA label change for Farxiga (dapagliflozin) from 2020 through 2026, including new indications for heart failure and CKD, safety warnings, and post-market surveillance findings.
A complete clinical and regulatory breakdown of Farxiga (dapagliflozin): FDA approval timeline, patent disputes, label updates, post-market safety signals, and what prescribers and patients need to know in 2025.
A comprehensive review of dapagliflozin (Farxiga) regulatory history, current FDA-approved indications, post-market safety surveillance, and emerging pipeline uses backed by primary clinical trial data.